| dbo:abstract
|
- OSU-6162 (PNU-96391) is a compound which acts as a partial agonist at both dopamine D2 receptors and 5-HT2A receptors. It acts as a dopamine stabilizer in a similar manner to the closely related drug pridopidine, and has antipsychotic, anti-addictive and anti-Parkinsonian effects in animal studies. Both enantiomers show similar activity but with different ratios of effects, with the (S) enantiomer (–)-OSU-6162 that is more commonly used in research, having higher binding affinity to D2 but is a weaker partial agonist at 5-HT2A, while the (R) enantiomer (+)-OSU-6162 has higher efficacy at 5-HT2A but lower D2 affinity. (en)
- OSU-6162 är ett delvis svenskutvecklat läkemedel med dopaminstabiliserande effekt. Läkemedlet har visat sig modulera tröskeln för belöningssystemet . I tidiga kliniska studier har substansen visat sig ha god effekt mot trötthet efter stroke. Läkemedlet verkar bland annat genom att blockera dopaminreceptorn D2, som har inhiberande effekter i centrala nervsystemet. OSU-6162 har i studier även visat sig ha effekter mot beroendetillstånd, parkinsons sjukdom, samt ha neuroleptiska egenskaper. (sv)
|
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:fdaUniiCode
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 9094 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:h
| |
| dbp:iupacName
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:s
| |
| dbp:smiles
|
- CCCN1CCC[C@H]C2=CCSC (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- GZVBVBMMNFIXGE-CQSZACIVSA-N (en)
|
| dbp:unii
| |
| dbp:width
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- OSU-6162 (PNU-96391) is a compound which acts as a partial agonist at both dopamine D2 receptors and 5-HT2A receptors. It acts as a dopamine stabilizer in a similar manner to the closely related drug pridopidine, and has antipsychotic, anti-addictive and anti-Parkinsonian effects in animal studies. Both enantiomers show similar activity but with different ratios of effects, with the (S) enantiomer (–)-OSU-6162 that is more commonly used in research, having higher binding affinity to D2 but is a weaker partial agonist at 5-HT2A, while the (R) enantiomer (+)-OSU-6162 has higher efficacy at 5-HT2A but lower D2 affinity. (en)
- OSU-6162 är ett delvis svenskutvecklat läkemedel med dopaminstabiliserande effekt. Läkemedlet har visat sig modulera tröskeln för belöningssystemet . I tidiga kliniska studier har substansen visat sig ha god effekt mot trötthet efter stroke. Läkemedlet verkar bland annat genom att blockera dopaminreceptorn D2, som har inhiberande effekter i centrala nervsystemet. OSU-6162 har i studier även visat sig ha effekter mot beroendetillstånd, parkinsons sjukdom, samt ha neuroleptiska egenskaper. (sv)
|
| rdfs:label
|
- OSU-6162 (en)
- OSU-6162 (sv)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
